Hormonal
Fibroblast growth factor 21 (FGF21) acts as a specific negative feedback signal that reduces carbohydrate (sweet) preference in response to high sugar intake.
High sugar intake triggers the release of FGF21, a hormone that naturally reduces your desire for sweets. Consistently high sugar intake may blunt this system or require higher thresholds to trigger it. Reducing initial sugar loads may help restore this natural regulatory feedback loop.
Circulating FGF21 activated hypothalamic PVN neurons and decreased sweet preference [102,103]. Therefore, FGF21 serves as a negative feedback signal to the CNS and regulates carbohydrate preference.
Why this rating
Supported by human data showing FGF21 peaks after sucrose challenges and animal studies showing causal links between FGF21 and reduced sweet preference.
Source
Neural and Molecular Mechanisms Involved in Controlling the Quality of Feeding Behavior: Diet Selection and Feeding Patterns
Tsutomu Sasaki · Nutrients · 2017
DOI 10.3390/nu9101151
More from this paper
- Loss-of-function mutations in the central melanocortin system (specifically MC4R, POMC, or AgRP pathways) consistently increase fat preference and decrease carbohydrate preference in both rodents and humans.Strong
- Modifying the sequence of macronutrient ingestion (specifically consuming protein before carbohydrates) improves post-prandial glycemic control by enhancing GLP-1 secretion and delaying gastric emptying, independent of total caloric intake.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →